BAXTER INTERNATIONAL INC acquired SuppreMol GmbH for ~$225M, a transaction completed in March 2015, structured as All-cash acquisition of a privately held company.
SuppreMol GmbH operates in BioScience, is based in Martinsried / Munich, Germany. Baxter acquired SuppreMol, a privately held biopharmaceutical company based in Martinsried, Germany that develops treatment options for autoimmune and allergic diseases, for EUR 200 million (approximately $225 million USD) before working capital and other adjustments. The deal included SuppreMol's early-stage portfolio of novel biologic immunoregulatory therapeutics focused on modulating Fc receptor signaling pathways, with lead candidate SM101 having completed Phase 2a studies in idiopathic thrombocytopenic purpura and systemic lupus erythematosus. Baxter also acquired and would continue to operate SuppreMol's Munich operations.
Complemented and built upon Baxter's differentiated immunology portfolio, expanding into new areas with significant market potential and unmet medical needs in autoimmune and allergic diseases.
Advisory firms were not disclosed for this transaction.